Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Aeglea Biothera (AGLE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 109,824
  • Shares Outstanding, K 16,640
  • Annual Sales, $ 4,630 K
  • Annual Income, $ -21,700 K
  • 36-Month Beta 2.31
  • Price/Sales 19.02
  • Price/Cash Flow N/A
  • Price/Book 1.92

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.86 +38.89%
on 12/20/17
6.88 -1.89%
on 01/19/18
+1.76 (+35.27%)
since 12/19/17
3-Month
3.75 +80.00%
on 11/30/17
6.88 -1.89%
on 01/19/18
+1.66 (+32.61%)
since 10/19/17
52-Week
2.81 +140.21%
on 08/17/17
8.14 -17.08%
on 03/20/17
+1.86 (+38.04%)
since 01/19/17

Most Recent Stories

More News
Aeglea BioTherapeutics to Present at BMO Capital Markets Prescriptions for Success Healthcare Conference

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to the discovery and development of engineered human enzyme therapeutics for patients with rare genetic diseases and cancer,...

AGLE : 6.75 (+2.27%)
Aeglea BioTherapeutics Doses First Pediatric Patient with Arginase 1 Deficiency in its Phase 1/2 Trial with Pegzilarginase (AEB1102)

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to the discovery and development of engineered human enzyme therapeutics for patients with rare genetic diseases and cancer,...

AGLE : 6.75 (+2.27%)
Aeglea BioTherapeutics Provides Corporate Update and Reports Third Quarter 2017 Financial Results

Aeglea BioTherapeutics, Inc., (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer, today...

AGLE : 6.75 (+2.27%)
Aeglea BioTherapeutics to Present Preclinical Data at 2017 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer, today...

AGLE : 6.75 (+2.27%)
Aeglea BioTherapeutics Announces Clinical Collaboration with Merck to Evaluate the Combination of Aeglea's AEB1102 (pegzilarginase) with Merck's KEYTRUDA(R) (pembrolizumab) for the Treatment of Small Cell Lung Cancer

Aeglea BioTherapeutics, Inc., (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer, today...

AGLE : 6.75 (+2.27%)
Aeglea BioTherapeutics Doses Two Patients in Repeat Dose Part of Phase 1/2 Clinical Trial for the Treatment of Arginase 1 Deficiency

Aeglea BioTherapeutics, Inc., (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer, today...

AGLE : 6.75 (+2.27%)
Aeglea BioTherapeutics to Present at the 2017 Wells Fargo Healthcare Conference

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer, today...

AGLE : 6.75 (+2.27%)
WFC : 64.22 (+0.42%)
Aeglea BioTherapeutics Provides Corporate Update and Reports Second Quarter 2017 Financial Results

Aeglea BioTherapeutics, Inc., (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer, today...

AGLE : 6.75 (+2.27%)
Aeglea BioTherapeutics Appoints James Wooldridge, M.D. as Chief Medical Officer

Aeglea BioTherapeutics, Inc., (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer, today...

AGLE : 6.75 (+2.27%)
LLY : 85.49 (-0.38%)
Endo Asked to Withdraw Pain Drug-Opana ER by FDA, Stock Down

Endo International plc (ENDP) received a huge setback when the FDA directed the company to voluntarily remove its opioid pain medication Opana ER (oxymorphone hydrochloride extended release) from the market...

AGLE : 6.75 (+2.27%)
ENDP : 7.11 (-3.27%)
VVUS : 0.47 (unch)
MEIP : 2.20 (+3.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More

Business Summary

Aeglea BioTherapeutics, Inc. is a biotechnology company which is engaged in developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer. Its portfolio of products consists of AEB1102, AEB3103, AEB2109 and AEB4104 which are in different clinical...

See More

Key Turning Points

2nd Resistance Point 7.16
1st Resistance Point 6.95
Last Price 6.75
1st Support Level 6.47
2nd Support Level 6.20

See More

52-Week High 8.14
Last Price 6.75
Fibonacci 61.8% 6.10
Fibonacci 50% 5.48
Fibonacci 38.2% 4.85
52-Week Low 2.81

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.